Herpes simplex virus type 1 (HSV-1) infection has a prevalence of 70% in the human population. Treatment is based on acyclovir, valacyclovir, and foscarnet, three drugs that share the same mechanism of action and of which resistant strains have been isolated from patients. In this aspect, innovative drug therapies are required. Natural products offer unlimited opportunities for the discovery of antiviral compounds. In this study, 28 extracts corresponding to 24 plant species and 4 alga species were assayed in vitro to detect antiviral activity against HSV-1. Six of the methanolic extracts inactivated viral particles by direct interaction and 14 presented antiviral activity when incubated with cells already infected. Most interesting antiviral activity values obtained are those of Limonium brasiliense, Psidium guajava, and Phyllanthus niruri, which inhibit HSV-1 replication in vitro with 50% effective concentration (EC 50 ) values of 185, 118, and 60 µg/mL, respectively. For these extracts toxicity values were calculated and therefore selectivity indexes (SI) obtained. Further characterization of the bioactive components of antiviral plants will pave the way for the discovery of new compounds against HSV-1.
Introduction
Herpes simplex virus type 1 (HSV-1), a member of the Herpesviridae family, is a double-stranded DNA virus, extremely widespread in the human population [1, 2] with prevalence ranging from 60 to more than 95% [3] . It is responsible for a broad range of disorders, including gingivostomatitis, keratoconjunctivitis, genital disease, and encephalitis [4] , causing more severe illnesses in newborns and immunocompromised patients [5] .
Several drugs, acyclovir, vidarabine, phosphonoformic acid, and other compounds including interferon, are used to treat HSV-associated diseases [6] . However, an increasing amount of drug-resistant strains have been isolated in the last few years, thus limiting the efficacy of these drugs [7] and enhancing the need for drugs that innovate in the viral targets or/and the mechanisms of action.
It is estimated that 40% of modern drugs derived from natural sources [8] . Ethnopharmacological knowledge and texts of traditional herbal medicine usage have been an important source of information and have shown to be very efficient in the identification of bioactive compounds, even when compared to the standard high volume random screening method [9] . South American flora has been explored for bioactive compounds with remarkable results, including the antioxidant properties of Achyrocline satureioides commonly known as "Marcela" [10] , capability of Phyllanthus niruri of dissolving kidney and gall stones [11] , and the Echinacea purpurea anti-influenza virus properties [12] .
Standardized cultivation of viruses is a powerful approach for in vitro drug testing that includes the possibility of comparison with reference drugs. The aim of this study was to challenge extracts of a set of South American plants to inhibit HSV-1 replication in a mammalian cell culture model.
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The Scientific World Journal For this, 28 ethanolic extracts corresponding to 24 plant and 4 alga species were prepared and assayed in vitro to detect selective antiviral activity. All species are found in Uruguayan soil and reports describing usage in traditional medicine exist for all of them. Moreover, some of the plants are specifically recommended to treat genital, throat, eyes, and mouth sores and itching. 
Materials and Methods

Plant and
Cells, Virus
, and Acyclovir. Vero cells (African green monkey kidney, ATCC number CCL-81) were cultured in D-MEM GlutaMAX-1 (Gibco Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Gibco Invitrogen), 100 µg/ mL Streptomycin, and 1000 U/mL penicillin and grown at 37
• C in a 5% CO 2 humidified atmosphere. The cell line used in this work was Mycoplasma sp. free. HSV-1 strain F was provided by Dra. Lucía Cavallaro from Cátedra de Virología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina. Acyclovir was purchased from Laboratorio Libra (Virulax 250) and prepared to 1 mg/mL in sterile water. 50 . To evaluate the effect of the extracts on Vero cells viability, dilutions ranging from 1000 to 16 µg/mL were added on 85-95% confluent monolayers in 96-well culture plates. After 72 hours of incubation, the maximum noncytotoxic concentration (MNCC) for all extracts was determined by microscopic observation and CC 50 (extract concentration that is toxic for half of the cells) was determined by the crystal violet uptake method. Briefly, cell monolayers were fixed and stained with a crystal violet 0.75% in 40% methanol solution and incubated for 15 minutes at 37
Determination of MNCC and CC
• C. Nonincorporated crystal violet dye was removed. Retained dye in the cells was solubilized with an acetic acid 20% solution, and the absorbance at 570 nm was measured in a microplate reader (Bio-Rad, Model 680).
Screening of Antiviral Activity by Cytopathic Effect Reduction Assay. Primary antiviral screening test was conducted
by cytopathic effect (CPE) reduction assay, which involves the protection of viral-caused lysis of Vero cells by extracts. Briefly, in 96-well culture plate, 5 × 10 4 UFP/mL of HSV-1 was inoculated on Vero cells. After 1 hour of adsorption at 37
• C in a 5% CO 2 humidified atmosphere, cells were washed with phosphate buffer saline (PBS) and 2-fold serial dilutions of the correspondent extract beginning at the MNCC were added. Cytotoxicity and cell controls were included. After 72 hours of incubation at 37
• C in a 5% CO 2 humidified atmosphere, cells were fixed and stained as described in Section 2.4. The antiherpetic activity of the extracts was evaluated by direct observation of CPE reduction. 50 by Plaque Reduction Assay. To determine the effective concentration that inhibited 50% of plaque forming units (PFUs) (EC 50 ) a standard plaque reduction assay was conducted. Briefly, Vero cells monolayers grown in 48-well culture plates were infected with 100 PFU of HSV-1. After 1 hour of adsorption at 37
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• C in a 5% CO 2 humidified atmosphere the cells were rinsed with PBS. Twofold serial dilutions of the correspondent extract (beginning from the MNCC) in medium containing 2% FBS and 0.8% methylcellulose were added. Each concentration was tested in duplicate. Infected cultures were incubated for 48 h at 37
• C in a 5% CO 2 humidified atmosphere. Cells were fixed and stained as described (see above). Plaques were counted and viral title expressed as PFU/well. Viral, cellular, and cytotoxic controls were performed in each assay. Acyclovir was included as a positive inhibition control.
Virucidal Activity Assay.
To evaluate the presence of virucidal activity, direct inactivation of HSV-1 by the extracts was tested. To assay virucidal activity, a 5 × 10 9 UFP/mL viral inoculum was mixed with extracts at three serial concentrations (MNCC, MNCC/2, and MNCC/4) and incubated at room temperature for 1 hour. After that, viral inoculum was diluted in medium supplemented with 2% FBS to a 500 UFP/ mL concentration. Surviving infectious viral particles were measured by standard plaque reduction assaywith respect to the control in which virus was mixed with medium supplemented with 2% FBS. Cell controls were included. Extract was considered positive when it inactivated ≥90% of the viral particles with respect to a control.
Data
Analysis. CC 50 and EC 50 for each extract were obtained from dose-effect curves (data not shown). The values correspond to the average and standard deviation of three independent assays with at least 5 concentrations within the inhibitory range. The selectivity index (IS) is defined as CC 50 /EC 50 .
Results
Among the 27 extracts tested only 16 plant species presented anti-HSV-1 activity. MNCC, EC 50 , and virucidal activity values obtained for each extract are showed in Table 1 . No antiviral activity was detected in the algae extracts. Extracts with anti-HSV-1 activity were also tested for virucidal activity. 
Discussion and Conclusions
The limited efficacy of the current treatment of HSV-1 infection enhances the need for novel therapies that include drugs with innovative viral targets and/or mechanisms of action. Since approximately 40% of modern drugs derived from natural sources and Ethnopharmacological knowledge has been an important source of information for the identification of bioactive compounds, we conducted this investigation with the aim to identify natural sources of compounds that could be potentially included in a formulation to be used in therapy against HSV-1. This work shows that ethanolic extracts of 16 plant species exhibit in vitro antiherpetic activity. The fact that 60% The Scientific World Journal of all the plants assayed resulted positive demonstrates once again that traditional knowledge of medicinal plant usage is an efficient way of identifying biological and particularly antimicrobial activity. Half of the 16 positive plants showed EC 50 values below 500 µg/mL, about ten times greater than that of acyclovir, which is a purified compound. Among these, P. niruri, Psidium incanum, and L. brasiliense showed the highest anti-HSV-1 activity as was determined in plaque reduction assay.
It is important to emphasize that the value obtained for P. niruri (EC 50 = 60 µg/mL) clearly correlates with its traditional use [13, 14] . In fact, this species is used to treat skin ulcers, sores, swelling, and itchiness of the skin [15] and other several illnesses including kidney and gall stones [9] , jaundice, gonorrhea, and diabetes [16] . It also has been tested for antiviral activity against influenza [17] , hepatitis B [18] [19] [20] , and human immunodeficiency virus (HIV) [16] . Our results are in accordance with previous reports of antiherpetic activity of several species of the Phyllanthus genera [21] [22] [23] [24] . With respect to P. guajava and L. brasiliense, there is no data about their antiherpetic activity. In fact, this is the first report demonstrating the inhibitory effect of HSV-1 replication in vitro of these plants. Remarkably, the three plant species have been widely used in traditional medicine by South American ancient populations for the treatment of several illnesses [13, 25] .
Since an antiviral compound should combine the highest effectiveness with the lowest cytotoxicity, it was important to evaluate the SI in order to determine the potential application of extract-derived compounds as antiviral agents. P. niruri has the highest SI resulting of a low CC 50 value combined with a high affectivity.
L. brasiliense has an encouraging value of antiviral effectivity (EC 50 = 185 µg/mL), but the ethanolic extract of this plant is also highly toxic resulting in an SI of 4.58. Since ethanolic extracts are complex and heterogeneous and compounds of different chemical origin are present, it might be possible to separate toxic molecules from those responsible of the antiviral activity. For these, further studies with purification fractions of the extract should be carried out.
On the other hand, it was important to differentiate direct viral particle inactivation from antiviral activity. In fact, virucidal activity might eclipse antiviral activity if tests of direct inactivation of viral particles are not performed. In our study, 6 plant extracts presented a positive activity (plaque reduction higher ≥ 90%). For this extracts one might assume that part of their activity relies on direct inactivation of the viral particles after virus adsorption and that this might also be occurring in the antiviral assay. However, this is not the case for extracts that combine low or no virucidal activity with positive antiviral activity (i.e., P. niruri, P. incanum, Apium leptophyllum, and Conyza bonariensis). For these anti-HSV-1 species another mechanism of action should exist since they act in postabsorption steps of the viral cycle.
The results presented here justify further investigation of the extracts by bioguided fractionation procedures that hopefully will allow to identify active molecule(s) involved in anti-HSV-1 activity. If purified compounds with at least the antiviral values showed here are identified, this will turn them into candidates for in vivo trials and future antiherpetic formulations.
